Access to Medicine Index homepage
'Live Well' social enterprise model builds local distribution networks in Zambia
6th Access to Medicine Index: latest analysis of pharma action.
The Index reports how 20 pharmaceutical companies make medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
Five companies are carrying out 63% of the most urgently needed R&D projects
Pharmaceutical R&D priorities have been identified for people in low- and middle-income countries. Companies are responding: priority R&D accounts for a fifth of all R&D projects analysed.
Most key on-patent products have access initiatives, but these are limited in reach
The Index has identified 53 products that are critical candidates for companies’ access initiatives: they are on-patent, first-line therapies seen as essential for all healthcare systems.
News related to the Access to Medicine Index
What leaders say
I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged.
President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)
The Access to Medicine Index is a very important project. What gets measured, gets done.
Dr. Margaret Chan
Former Director General, World Health Organisation
When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that.
Co-chair and Trustee, Bill & Melinda Gates Foundation
"There have been massive improvements in global health in the past decades, with all major pharmaceutical companies taking action. To close the gaps that remain, a greater diversity of companies must get involved and stay engaged."
Jayasree K. Iyer
Executive Director Access to Medicine Foundation
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.